Literature DB >> 1784141

Comparative study of the adverse effects of various radiographic contrast media, including ioversol, a new low-osmolarity medium. II. The complement system and endothelial cells.

M Akagi1, S Masaki, K Kitazumi, M Mio, K Tasaka.   

Abstract

The effects of ioversol, iohexol, iopamidol and meglumine sodium amidotrizoate (MSA) on the complement system and endothelial cells were investigated. The protein bindings of the radiographic contrast media (RCM), each tested with guinea pig plasma, were less than 1%. When guinea pig serum was incubated with any of the RCM, activation of the complement system, which leads to hemolysis, was not influenced by the nonionic agents, ioversol, iohexol or iopamidol. However, MSA, an ionic agent, significantly reduced hemolytic activity at 370 mgI/ml. Perfusion of the abdominal aorta with nonionic agents did not elicit significant endothelial damage; ioversol induced the least damage among the nonionic RCM, while MSA caused remarkable endothelial damage. Although MSA caused a marked release of endothelin-1 from cultured endothelial cells obtained from porcine aorta, nonionic RCM did not induce significant endothelin-1 release; no influence was elicited by ioversol and iohexol caused a weak suppression, while iopamidol had the opposite effect. These results indicate that ioversol could be used as a safe contrast medium in intravascular administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1784141

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  2 in total

1.  The relative safety of MRI contrast agent in acute necrotizing pancreatitis.

Authors:  J Werner; J Schmidt; A L Warshaw; M M Gebhard; C Herfarth; E Klar
Journal:  Ann Surg       Date:  1998-01       Impact factor: 12.969

2.  Intravenous contrast medium aggravates the impairment of pancreatic microcirculation in necrotizing pancreatitis in the rat.

Authors:  J Schmidt; H G Hotz; T Foitzik; E Ryschich; H J Buhr; A L Warshaw; C Herfarth; E Klar
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.